Literature DB >> 21217655

Cancer drugs should add months, not weeks, say experts.

Hannah Hoag.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21217655     DOI： 10.1038/nm0111-7a

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  3 in total

1.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Marc Peeters; Salvatore Siena; Yves Humblet; Alain Hendlisz; Bart Neyns; Jean-Luc Canon; Jean-Luc Van Laethem; Joan Maurel; Gary Richardson; Michael Wolf; Rafael G Amado
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

2.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

Review 3.  International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

Authors:  Olivia Pagani; Elzbieta Senkus; William Wood; Marco Colleoni; Tanja Cufer; Stella Kyriakides; Alberto Costa; Eric P Winer; Fatima Cardoso
Journal:  J Natl Cancer Inst       Date:  2010-03-10       Impact factor: 13.506
  3 in total
  2 in total

1.  New drugs: evidence relating to their therapeutic value after introduction to the market.

Authors:  Mariam Ujeyl; Claudia Schlegel; Siegbert Walter; Ursula Gundert-Remy
Journal:  Dtsch Arztebl Int       Date:  2012-02-17       Impact factor: 5.594

2.  Pragmatic medicine in solid cancer: a translational alternative to precision medicine.

Authors:  Jan Brábek; Daniel Rosel; Michael Fernandes
Journal:  Onco Targets Ther       Date:  2016-04-05       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.